180 related articles for article (PubMed ID: 32891532)
1. Pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups.
Tanaka H; Hijioka S; Hosoda W; Ueno M; Kobayashi N; Ikeda M; Ito T; Kodama Y; Morizane C; Notohara K; Taguchi H; Kitano M; Komoto I; Tsuji A; Hashigo S; Kanno A; Miyabe K; Takagi T; Ishii H; Kojima Y; Yoshitomi H; Yanagimoto H; Furuse J; Mizuno N
Pancreatology; 2020 Oct; 20(7):1421-1427. PubMed ID: 32891532
[TBL] [Abstract][Full Text] [Related]
2. Rb Loss and
Hijioka S; Hosoda W; Matsuo K; Ueno M; Furukawa M; Yoshitomi H; Kobayashi N; Ikeda M; Ito T; Nakamori S; Ishii H; Kodama Y; Morizane C; Okusaka T; Yanagimoto H; Notohara K; Taguchi H; Kitano M; Yane K; Maguchi H; Tsuchiya Y; Komoto I; Tanaka H; Tsuji A; Hashigo S; Kawaguchi Y; Mine T; Kanno A; Murohisa G; Miyabe K; Takagi T; Matayoshi N; Yoshida T; Hara K; Imamura M; Furuse J; Yatabe Y; Mizuno N
Clin Cancer Res; 2017 Aug; 23(16):4625-4632. PubMed ID: 28455360
[No Abstract] [Full Text] [Related]
3. Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas?
Hijioka S; Hosoda W; Mizuno N; Hara K; Imaoka H; Bhatia V; Mekky MA; Tajika M; Tanaka T; Ishihara M; Yogi T; Tsutumi H; Fujiyoshi T; Sato T; Hieda N; Yoshida T; Okuno N; Shimizu Y; Yatabe Y; Niwa Y; Yamao K
J Gastroenterol; 2015 May; 50(5):564-72. PubMed ID: 25142799
[TBL] [Abstract][Full Text] [Related]
4. Platinum-Based Treatment for Well- and Poorly Differentiated Pancreatic Neuroendocrine Neoplasms.
Pulvirenti A; Raj N; Cingarlini S; Pea A; Tang LH; Luchini C; Chou JF; Grego E; Marinova I; Capanu M; Landoni L; Scarpa A; Allen PJ; Klimstra DS; Reidy-Lagunes DL
Pancreas; 2021 Feb; 50(2):138-146. PubMed ID: 33565789
[TBL] [Abstract][Full Text] [Related]
5. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
6. Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated.
Raj N; Valentino E; Capanu M; Tang LH; Basturk O; Untch BR; Allen PJ; Klimstra DS; Reidy-Lagunes D
Pancreas; 2017 Mar; 46(3):296-301. PubMed ID: 27759713
[TBL] [Abstract][Full Text] [Related]
7. Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.
Umetsu SE; Kakar S; Basturk O; Kim GE; Chatterjee D; Wen KW; Hale G; Shafizadeh N; Cho SJ; Whitman J; Gill RM; Jones KD; Navale P; Bergsland E; Klimstra D; Joseph NM
Mod Pathol; 2023 Mar; 36(3):100065. PubMed ID: 36788102
[TBL] [Abstract][Full Text] [Related]
8. Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms.
Elvebakken H; Hjortland GO; Garresori H; Andresen PA; Janssen EAM; Vintermyr OK; Lothe IMB; Sorbye H
J Neuroendocrinol; 2023 Apr; 35(4):e13256. PubMed ID: 37017614
[TBL] [Abstract][Full Text] [Related]
9. The Eighth Edition of the American Joint Committee on Cancer Distant Metastases Stage Classification for Metastatic Pancreatic Neuroendocrine Tumors Might Be Feasible for Metastatic Pancreatic Ductal Adenocarcinomas.
Wen J; Chen J; Liu D; Xu X; Fan M; Zhang Z
Neuroendocrinology; 2020; 110(5):364-376. PubMed ID: 31357196
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.
Zhu X; Salhab M; Tomaszewicz K; Meng X; Mathew C; Bathini V; Switzer B; Walter O; Cosar EF; Wang X; Lambert LA; Hutchinson LM
Hum Pathol; 2019 Mar; 85():260-269. PubMed ID: 30458197
[TBL] [Abstract][Full Text] [Related]
12. Clinical Impact of KRAS and GNAS Analysis Added to CEA and Cytology in Pancreatic Cystic Fluid Obtained by EUS-FNA.
Faias S; Duarte M; Albuquerque C; da Silva JP; Fonseca R; Roque R; Dias Pereira A; Chaves P; Cravo M
Dig Dis Sci; 2018 Sep; 63(9):2351-2361. PubMed ID: 29796909
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
Fazio N; Milione M
Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
[TBL] [Abstract][Full Text] [Related]
14. Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma.
Shamir ER; Devine WP; Pekmezci M; Umetsu SE; Krings G; Federman S; Cho SJ; Saunders TA; Jen KY; Bergsland E; Jones K; Kim GE; Kakar S; Chiu CY; Joseph NM
Mod Pathol; 2019 Feb; 32(2):290-305. PubMed ID: 30237525
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study.
Kim H; An S; Lee K; Ahn S; Park DY; Kim JH; Kang DW; Kim MJ; Chang MS; Jung ES; Kim JM; Choi YJ; Jin SY; Chang HK; Cho MY; Kang YK; Kang M; Ahn S; Kim YW; Hong SM;
Cancer Res Treat; 2020 Jan; 52(1):263-276. PubMed ID: 31319641
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of rapid on-site evaluation specimens from endoscopic ultrasound-guided fine-needle aspiration for cancer gene panel testing: A retrospective study.
Ishizawa T; Makino N; Matsuda A; Kakizaki Y; Kobayashi T; Ikeda C; Sugahara S; Tsunoda M; Ueno Y
PLoS One; 2020; 15(1):e0228565. PubMed ID: 31999789
[TBL] [Abstract][Full Text] [Related]
17. Assessment of cytologic differentiation in high-grade pancreatic neuroendocrine neoplasms: A multi-institutional study.
Sigel CS; Krauss Silva VW; Reid MD; Chhieng D; Basturk O; Sigel KM; Daniel TD; Klimstra DS; Tang LH
Cancer Cytopathol; 2018 Jan; 126(1):44-53. PubMed ID: 29044913
[TBL] [Abstract][Full Text] [Related]
18. [Responsiveness of well-differentiated PanNET G3 to platinum-based chemotherapy: a case report].
Kojima E; Kuba H; Matsumura M
Nihon Shokakibyo Gakkai Zasshi; 2019; 116(11):952-959. PubMed ID: 31708508
[TBL] [Abstract][Full Text] [Related]
19. World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution.
Yang M; Zeng L; Ke NW; Tan CL; Tian BL; Liu XB; Xiang B; Zhang Y
BMC Cancer; 2020 Sep; 20(1):906. PubMed ID: 32962649
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Local Recurrence of Pancreatic Cancer by KRAS Mutation Analysis Using Washes from Endoscopic Ultrasound-Guided Fine-Needle Aspiration.
Matsumoto K; Kato H; Nouso K; Ako S; Kinugasa H; Horiguchi S; Saragai Y; Takada S; Yabe S; Muro S; Uchida D; Tomoda T; Okada H
Dig Dis Sci; 2020 Oct; 65(10):2907-2913. PubMed ID: 31897893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]